Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China.

about

Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China

P2860

Q33916649-672A5C4F-BCD8-48D2-90FB-6FFE9FE9EE11

P2860

Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China.

Item

http://www.wikidata.org/entity/Q36183172

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Estimating long-term clinical ...... of HPV 16/18 vaccine in China.

@ast

Estimating long-term clinical ...... of HPV 16/18 vaccine in China.

@en

type

Item

label

Estimating long-term clinical ...... of HPV 16/18 vaccine in China.

@ast

Estimating long-term clinical ...... of HPV 16/18 vaccine in China.

@en

prefLabel

Estimating long-term clinical ...... of HPV 16/18 vaccine in China.

@ast

Estimating long-term clinical ...... of HPV 16/18 vaccine in China.

@en

P1476

Estimating long-term clinical ...... of HPV 16/18 vaccine in China

@en

P2093

Qian Zhang

http://www.w3.org/2001/XMLSchema#string

Shang-Ying Hu

http://www.w3.org/2001/XMLSchema#string

Yi-Jun Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Human Papillomavirus (HPV)-associated Oral Cancers and Treatment Strategies

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review

Epidemiologic classification of human papillomavirus types associated with cervical cancer

The impact of HPV vaccination delays in China: lessons from HBV control programs.

Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China.

A multi-center survey of HPV knowledge and attitudes toward HPV vaccination among women, government officials, and medical personnel in China.

Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries

Cost-effectiveness of a potential vaccine for human papillomavirus.

P2888

s12885-016-2893-x

P304

848

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-016-2893-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

F H Zhao

P577

2016-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1025383330

http://www.w3.org/2001/XMLSchema#string

P698

27814703

http://www.w3.org/2001/XMLSchema#string

P932

5097411

http://www.w3.org/2001/XMLSchema#string

Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China.

about

P2860

P2860

Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932